This is one of two replicate randomized, double-blind, placebo-controlled, parallel arm trials to determine the safety and efficacy of two different dose levels of SEL-212 compared to placebo. 112 and 153 patients, stratified as to the presence or absence of tophi, were randomized in a 1:1:1 allocation ratio prior to Baseline to receive treatment with one of two dose levels of SEL-212 or placebo every 28 days for approximately 6 months in each trial respectively (SEL-212/301 and SEL-212/302). Analysis of primary and key efficacy were performed at Day 28 of Treatment Period 6. Safety was monitored throughout the study.

开始日期2020-11-30

申办/合作机构

Swedish Orphan Biovitrum AB

NCT04513366

/ Completed临床3期

A Randomized Double-Blind, Placebo-Controlled Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy

This is one of two replicate randomized, double-blind, placebo-controlled, parallel arm trials to determine the safety and efficacy of two different dose levels of SEL-212 compared to placebo. 112 and 153 patients, stratified as to the presence or absence of tophi, were randomized in a 1:1:1 allocation ratio prior to Baseline to receive treatment with one of two dose levels of SEL-212 or placebo every 28 days for approximately 6 months in each trial respectively (SEL-212/301 and SEL-212/302). Analysis of primary and key efficacy was performed at Day 28 of Treatment Period 6. Safety was monitored throughout the study.

开始日期2020-08-18

申办/合作机构

Swedish Orphan Biovitrum AB

NCT03905512

/ Completed临床2期

A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy

This is a randomized, parallel-arm, multicenter study to compare the safety and efficacy profiles of SEL-212 and KRYSTEXXA®. Participants will be randomized 1:1 to receive treatment with SEL-212 or KRYSTEXXA® for 6 months. Efficacy assessments, as measured by serum uric acid (SUA) levels, will be conducted at intervals that are appropriate to determine treatment effect differences. Safety will be monitored throughout the study.

开始日期2019-05-07

申办/合作机构

Selecta Biosciences, Inc.

100 项与 SEL-212 相关的临床结果

登录后查看更多信息

100 项与 SEL-212 相关的转化医学

登录后查看更多信息

100 项与 SEL-212 相关的专利（医药）

登录后查看更多信息

项与 SEL-212 相关的文献（医药）

2026-03-31·International Heart Journal

Cost-Effectiveness Analysis of Implementing the Nagasaki Acute Myocardial Infarction Secondary Prevention Clinical Pathway

Article

作者: Inoue, Sachie ; Yoshimura, Mizuki ; Yamanaka, Yosuke ; Ikeda, Satoshi ; Kurobe, Masaya ; Mori, Katsuya ; Maemura, Koji ; Uda, Akihito ; Igarashi, Ataru

Due to the poor prognosis associated with acute coronary syndromes (ACSs), intensive low-density lipoprotein cholesterol (LDL-C) management therapy is recommended as early as possible after the onset of ACS, with the goal of lowering plasma LDL-C to < 70 mg/dL. The purpose of this study was to evaluate the cost-effectiveness of implementing the Nagasaki Acute Myocardial Infarction Secondary Prevention Clinical Pathway (NASP) using medical records (n = 385, pre-implementation group:224, post-implementation group:161) extracted from 8 hospitals in Nagasaki.Cost-effectiveness of implementing NASP was evaluated by a lifetime simulation using mathematical models. Drug costs for lipid-lowering therapy were calculated from actual prescriptions and treatment costs for each cardiovascular disease (CVD) event and utility scores were based on the literature. The risk of each CVD event was estimated by the equation consisting of the following variables: LDL-C, baseline CVD risks estimated using real-world clinical practice data, rate ratio per unit change in LDL-C and age. Implementation of NASP was evaluated as dominant, with an incremental gain of 0.058 quality-adjusted life years (QALYs) and expected cost savings of JPY 59,507 per person.Implementing NASP can be expected to reduce costs, in addition to increasing QALYs by preventing CVD. Further clinical and economic evaluation of long-term follow-up with a collaborative pathway to the general physician after discharge from the hospital is expected.

2026-03-01·DRUGS

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) in Uncontrolled Gout: Current Status and Future Directions

Review

作者: Baraf, Herbert S B ; Strand, Vibeke ; Schlesinger, Naomi

Uncontrolled gout (UG) is a progressive arthropathy that develops as a consequence of sustained hyperuricemia. Recombinant uricases can profoundly lower serum urate (SU) and reverse the clinical manifestations of uncontrolled gout. However, therapeutic uricases are highly immunogenic and can provoke the development of anti-drug antibodies (ADAs), resulting in a loss of effect and potentially severe allergic reactions. Pegloticase is currently the only US Food and Drug Administration-approved uricase indicated for the treatment of UG. The Food and Drug Administration recently approved the co-administration of methotrexate with pegloticase to inhibit ADA formation and enhance the efficacy and tolerability of pegloticase. Nanoencapsulated sirolimus plus pegadricase (NASP) is a novel every-4-week treatment delivered as a sequential two-component infusion consisting of nanoencapsulated sirolimus immediately followed by pegadricase, a novel PEGylated uricase. NASP mitigates ADA formation by promoting uricase-specific immunotolerance, thereby obviating the need for systemic immunomodulatory drugs. Phase I trials demonstrated that NASP inhibited ADA development, allowing sustained pegadricase control and SU lowering for up to 30 days. The dose-finding (phase II) study showed NASP (nanoencapsulated sirolimus 0.1-0.15 mg/kg and pegadricase 0.2 mg/kg) reduced ADA development and supported durable SU lowering. The phase II COMPARE trial demonstrated that monthly NASP was as effective as twice-monthly pegloticase in achieving SU targets at 6 months. Combined phase III DISSOLVE trial data confirmed that NASP significantly lowered SU and increased SU responses in participants with UG. All phase I-III trials demonstrated that NASP was generally well tolerated with no specific safety signals. Overall, NASP has demonstrated robust and durable SU lowering, which ultimately reduced disease burden, supporting positive health-related quality-of-life outcomes. This review summarizes the clinical development of NASP with particular reference to the targeted immunotolerizing strategy that diminishes its immunogenicity. Video abstract available online. Video Abstract.

2024-04-02·Rheumatology (Oxford, England)

The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout

Article

作者: DeHaan, Wesley ; Azeem, Rehan ; Kivitz, Alan J ; Traber, Peter G ; Choi, Hyon K ; Baraf, Herbert S B ; Strand, Vibeke ; Terkeltaub, Robert ; Keenan, Robert T ; Dalbeth, Nicola ; Khanna, Puja P

Abstract:

Objectives:

Serum urate (SU) lowering with PEGylated uricases in gout can reduce flares and tophi. However, treatment-emergent anti-drug antibodies adversely affect safety and efficacy and the currently approved PEGylated uricase pegloticase requires twice-monthly infusions. Investigational SEL-212 therapy aims to promote uricase-specific tolerance via monthly sequential infusions of a proprietary rapamycin-containing nanoparticle (ImmTOR) and pegadricase.

Methods:

COMPARE was a randomized, phase 2, open-label trial of SEL-212 vs pegloticase in adults with refractory gout. SEL-212 [ImmTOR (0.15 mg/kg) and pegadricase (0.2 mg/kg)] was infused monthly or pegloticase (8 mg) twice monthly for 6 months. The primary endpoint was the proportion of participants with SU <6 mg/dl for ≥80% of the time during 3 and 6 months. Secondary outcomes were mean SU, gout flares, number of tender and/or swollen joints and safety.

Results:

During months 3 and 6 combined, numerically more participants achieved and maintained a SU <6 mg/dl for ≥80% of the time with SEL-212 vs pegloticase (53.0% vs 46.0%, P = 0.181). The percentage reductions in SU levels were statistically greater during months 3 and 6 with SEL-212 vs pegloticase (−73.79% and −47.96%, P = 0.0161). Reductions in gout flare incidence and number of tender and/or swollen joints were comparable between treatments. There were numerical differences between the most common treatment-related adverse events of interest with SEL-212 and pegloticase: gout flares (60.2% vs 50.6%), infections (25.3% vs 18.4%) and infusion-related reactions (15.7% vs 11.5%), respectively. Stomatitis (and related terms) was experienced by eight participants (9.6%) with SEL-212 and none with pegloticase. Stomatitis, a known event for rapamycin, was associated with ImmTOR only.

Conclusions:

SEL-212 efficacy and tolerability were comparable to pegloticase in refractory gout. This was associated with a substantial reduction in treatment burden with SEL-212 due to decreased infusion frequency vs pegloticase.

Clinical trial registration:

NCT03905512.

项与 SEL-212 相关的新闻（医药）

2026-04-12

·今日头条

痛风治疗新进展

痛风治疗正经历从“一刀切”到“分型而治”的重大变革，中国指南已率先将非布司他推荐为无症状高尿酸血症的一线药物，同时多种创新疗法取得突破 1. 核心进展：非布司他开启新时代非布司他作为新型黄嘌呤氧化酶抑制剂，其精准的作用机制使其能有效阻断尿酸的生成，在降低血尿酸水平方面表现出色-。2025年更新的《中国高尿酸血症和痛风诊治指南》进一步巩固了其核心地位，在多项重要调整中，将其推荐为无症状高尿酸血症患者的一线降尿酸药物--41。这一地位的提升，是其在特定人群中疗效与安全性得到临床验证的重要标志。 2. 前沿突破：新靶点药物研发非布司他的崛起并非终点，针对不同发病机制的新型药物正在快速推进，其中最引人注目的是对难治性痛风的突破：尿酸氧化酶（酶替代疗法）：针对传统口服药物效果不佳的难治性痛风，通过注射给药，直接将尿酸分解为可溶性物质排出体外。例如，NASP (SEL-212) 是一种长效注射疗法，其III期临床数据显示，高剂量组 51% 的患者在第6个月时能够维持血尿酸达标-60。该药的上市申请已获美国FDA受理，有望在2026年做出审批决定-。其他前沿技术：此外，基于mRNA的酶替代疗法也已进入临床试验阶段-，而口服工程酶药物则为无法使用传统注射方式的患者提供了新选择-。 3. 应用基石：规范使用，安全为先所有新型药物的应用都必须建立在严格的规范之上，以确保患者安全。非布司他的使用尤其需要遵循精准、个体化的原则。避免一刀切：非布司他通过减少尿酸生成起效，适用于尿酸生成过多的患者（约占60%）；而新型URAT1抑制剂则通过促进尿酸排泄，更适合尿酸排泄减少的患者-7。警惕心血管风险：这是使用非布司他的关键安全考量。多项研究表明，使用非布司他比使用别嘌醇的患者发生心血管血栓事件（如心血管死亡、心肌梗死）的风险更高，原因尚不明确-。因此，对于原有重大心血管疾病（如心肌梗死、卒中）的患者，应避免使用，除非无其他选择-。遵循临床指南：2025年的中国指南强调了“根据高尿酸血症的病理生理类型进行个体化制定”降尿酸治疗方案的原则-41。这意味着医生需要为患者进行精准分型后，再选择最合适的药物和剂量。 4. 评析总体而言，非布司他地位的提升和新疗法的涌现，标志着痛风治疗正式进入了一个基于病理生理机制的精准治疗时代。这一变革有效弥补了传统药物“一刀切”模式的不足，为不同病因的患者提供了更多元、更有效的选择。然而，机遇与挑战并存。新疗法，尤其是生物制剂和基因治疗，预计成本较高，其医疗经济学价值和广泛可及性将是未来需要解决的关键问题。在中国，这一变革已初现端倪：新型URAT1抑制剂多替诺雷已于2025年12月成功纳入国家医保目录，自2026年1月1日起执行，有效降低了患者的用药负担--58。因此，当前的核心是确保这些前沿进展能安全、规范地转化为临床实践。这需要医生在繁忙的临床工作中，不断更新知识，准确为患者进行分型诊断，并严格执行个体化用药原则，在确保疗效的同时，最大限度规避风险。

2026-03-30

·病因知识科普

痛风系列讲座·第4篇--2026重磅！痛风生物制剂来了，难治性痛风的新希望！

字数：约2114字阅读时间：约8分钟一、什么是难治性痛风？门诊里，58岁的老李愁眉苦脸： "医生，我别嘌醇吃到800mg了，非布司他也试过，尿酸还是降不下来。双手长满痛风石，连筷子都拿不稳……" 检查发现：血尿酸：612 μmol/L（目标<300）双手多发痛风石，最大直径3.5cm 肾功能：GFR 38（中度肾功能不全）每月痛风发作2-3次这就是典型的难治性痛风。📊难治性痛风的定义与现状 2020年ACR定义[1]：为什么会难治？[2][3] 老李的经历就是典型：别嘌醇800mg：尿酸仅降至480 μmol/L 非布司他80mg：肝酶升高，被迫停药苯溴马隆：肾功能不全禁用，有肝损伤风险痛风石持续增大，生活质量极差在2023年前，这类患者几乎无药可用。二、生物制剂：革命性突破生物制剂的出现，彻底改变了难治性痛风的治疗格局。💡传统药物与生物制剂对比痛风生物制剂两大类： 1、抗炎生物制剂：阻断IL-1β炎症通路代表：卡那单抗（Canakinumab） 2、尿酸酶类：直接降解尿酸第一代：培戈洛酶（Pegloticase，有严重缺陷）第二代：NASP（SEL-212，革命性改进）三、卡那单抗：首个获批的痛风生物制剂💊基本信息通用名：Canakinumab商品名：Ilaris（伊拉利司）上市时间：2023年8月（FDA批准痛风适应症）类型：完全人源化单克隆抗体里程碑意义：首个且唯一获批用于痛风的生物制剂开创了痛风生物治疗新时代🔬作用机制回顾第一篇讲过的痛风发病机制：痛风系列讲座·第1篇--痛风年轻化警报！为什么你30岁就中招了？卡那单抗的精准打击[4]：核心优势：只针对IL-1β（靶向治疗）不影响其他免疫功能长效（半衰期26天）📊疗效数据 β-RELIEVED研究（2016）[4]：关键的III期临床试验，奠定了卡那单抗在痛风治疗中的地位。关键发现：一针的效果持续近3个月！这是传统药物完全无法比拟的。💰价格与可及性美国定价[5]：单次注射：18,000-20,000美元（约13-14万人民币）如按3个月用1次计算：年费用约72,000-80,000美元（约50-56万人民币）中国情况：审批状态：已提交上市申请（2024年）预计时间：2025-2026年获批预计价格：12,000-15,000元/支（参考其他适应症定价）医保谈判：可能性大（类比PD-1等生物制剂经验）进医保后：可能降至5,000-8,000元/支🎯适合人群适合： ✓急性痛风发作 ✓NSAIDs/秋水仙碱/激素都禁忌或不耐受[6] ✓经济条件允许 ✓希望长效控制的患者不适合：仅作为降尿酸治疗（无此作用）预防痛风发作（未批准此适应症）长期频繁使用（每年限定次数）重要：卡那单抗只治疗急性发作，不降尿酸，必须联合降尿酸药物。四、NASP（SEL-212）：2026年最重磅新药如果说卡那单抗是治"标"（炎症），那么NASP就是治"本"（尿酸）。💊基本信息正式名称：SEL-212 组成：NAS + Pegadricase NAS：纳米包裹的西罗莫司 Pegadricase：聚乙二醇化尿酸氧化酶⭐重大事件时间线 2023年：完成III期DISSOLVE临床试验 2024年9月： FDA接受生物制剂许可申请（BLA） 2026年6月27日：PDUFA目标批准日期预计：2026年下半年上市这可能是2026年痛风领域最重磅的新闻！🔬革命性创新：解决培戈洛酶致命缺陷要理解NASP的价值，先要知道第一代尿酸酶的失败。第一代：培戈洛酶（Pegloticase）的困境[7]： NASP的突破性设计[8][9]： 📊临床试验数据 DISSOLVE-I和DISSOLVE-II研究[8][9]：这是决定NASP命运的关键III期试验。安全性[8][9]：主要不良反应：输液反应：6.8%（vs 培戈洛酶25-30%）大幅改善！感染：8.2%多为轻度上呼吸道感染严重不良事件：2.3%（可接受）无死亡病例🎯适应症（预期） FDA预期批准适应症：难治性慢性痛风定义：传统降尿酸药（XOI）无效或不耐受血尿酸持续>360 μmol/L 有症状的痛风石频繁痛风发作五、卡那单抗 vs NASP：如何选择？六、未来展望💡个体化治疗时代 2026年后的痛风治疗将是：结语：难治性痛风不再绝望生物制剂的出现，彻底改变了难治性痛风的治疗格局。记住关键点：卡那单抗（llaris）：2023 年FDA批准，首个痛风生物制剂治疗急性发作，长效抗炎一针管3个月⚠️ 不降尿酸，需联合传统药 NASP（SEL-212）：2026 年6月27日可能FDA批准治疗难治性慢性痛风强效降尿酸+快速消痛风石解决培戈洛酶抗体问题对于难治性痛风患者：不要放弃希望新药正在快速进入临床与医生讨论是否适合生物制剂关注医保政策变化但也要记住：生物制剂不是万能的生活方式管理仍然重要预防永远胜于治疗早诊早治，避免成为难治性痛风下期预告：下期我们将详细讲解痛风饮食管理——最新嘌呤表、功能性食物、饮食策略。这是最实用、最贴近生活的一期，千万别错过！关注我，不错过痛风系列的每一期。您的健康，值得我们共同守护本文数据来源于以下权威医学期刊和指南： [1] FitzGerald JD, et al. 2020 American College of Rheumatology Guideline for the Management of Gout.Arthritis Care Res (Hoboken). 2020;72(6):744-760. [2] Dalbeth N, et al. Gout.Lancet. 2016;388(10055):2039-2052. [3] Pascart T, Richette P. Refractory gout.Joint Bone Spine. 2022;89(2):105279. [4] Solomon DH, et al. Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial.Ann Intern Med. 2018;169(8):535-542. [5] Novartis官方定价信息，2023年9月公布. [6] FDA. Ilaris (canakinumab) Prescribing Information. 2023年8月批准文件. [7] Sundy JS, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment.JAMA. 2011;306(7):711-720. [8] Lipsky PE, et al. SEL-212: A Novel, Subcutaneous, Pegylated Uricase Combined with an Immunomodulator (SEL-110) for the Treatment of Refractory Gout: Phase 2 Results.Arthritis Rheumatol. 2020;72(suppl 10). (DISSOLVE-I研究) [9] Mandell BF, et al. SEL-212/DISSOLVE-II: a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Pegadricase Plus Sirolimus (SEL-212) in Patients With Uncontrolled Gout.Arthritis Rheumatol. 2023;75(suppl). (DISSOLVE-II研究结果，会议摘要) 注：NASP（SEL-212）的III期完整数据尚未在同行评审期刊正式发表，以上数据来自Selecta Biosciences公司2023-2024年公开的临床试验结果和FDA申报文件。正式出版物预计在FDA批准后发表。免责声明：本文仅供健康科普，不能替代医生诊疗建议。如有症状，请及时就医。

临床3期

2026-02-18

·PRNewswire

Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030

STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today hosts its Capital Markets Day, where senior management will provide an update on the company's strategy and outline its new mid-term outlook, aiming to achieve SEK 55bn revenue by 2030, while building a resilient platform for sustained growth beyond 2030. Sobi aims to have an adjusted EBITA margin in the upper 30s percentage of revenue by 2030. Sobi has delivered strong and profitable growth in recent years, transforming and diversifying its portfolio and positioning the company to deliver on six major launches. Additionally, Sobi is advancing priority development programs enabling longer term growth and continuing its international expansion. "Sobi today is a stronger, more global and more scientifically driven company," says Guido Oelkers, CEO of Sobi. "We have delivered on our commitments, built a diversified, robust foundation for future growth, and are entering the next phase of expansion with multiple launches and compelling opportunities to unlock growth well beyond 2030." Highlights of the Capital Markets Day Sobi shares its ambition to reach SEK 55bn in revenues by 2030, effectively doubling the company revenue driven by six major launches, continued strong performance of strategic products, and international expansion. Sobi outlines major launches either ongoing or in preparation, expected to drive the majority of growth to 2030, including Altuvoct®, Gamifant®, Aspaveli®, Tryngolza®, NASP, and pozdeutinurad, across haematology, immunology, and specialty care. Deep dives demonstrate Sobi's scientific leadership in: Uncontrolled and progressive gout and two potentially transformative treatment innovations in an area of high unmet patient needs. Severe hypertriglyceridemia, where acute pancreatitis is a major risk and a severe medical emergency, and ApoC-III inhibition with olezarsen has shown significant and meaningful reductions in acute pancreatitis risk. Precision medicine in sepsis: In biomarker-selected patients with interferon gamma-driven sepsis (the proof-of-concept EMBRACE study), Sobi will share topline data for empalumab demonstrating improvement in SOFA-based organ function (achieving primary endpoint at end of treatment in 60% patients receiving high dose emapalumab vs 40% in the standard of care plus placebo arm). High dose emapalumab additionally showed a 12-percentage point absolute mortality reduction after 28-days (40% mortality in the high dose emapalumab arm vs 52% in the standard of care plus placebo arm). Additional information provided New peak sales expectations for the following products: Haemophilia A franchise (Altuvoct and Elocta) greater than SEK 10bn, Aspaveli between SEK 7-10bn, Gamifant in HLH between SEK 5-7bn, NASP between SEK 4-6bn, Tryngolza greater than SEK 10bn, pozdeutinurad greater than SEK 10bn and Gamifant in IDS greater than SEK 10bn. R&D expenses to remain between 11-14 per cent of sales on a given year between now and 2030. Agenda in brief The Capital Markets Day includes presentations from Sobi's executive leadership on strategy, pipeline and innovation, commercial opportunities and financial outlook as well as disease deep dives with experts and leaders in their respective fields, and a concluding Q&A session. Pre-registration for online attendance: click here A recording of the presentations and supporting materials will be made available on . Sobi Sobi® is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2025 revenue amounted to SEK 28 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:00 CET on 18 February 2026. Gerard Tobin Head of Investor Relations This information was brought to you by Cision The following files are available for download: SOURCE Swedish Orphan Biovitrum AB 21% more press release views with Request a Demo

临床结果

100 项与 SEL-212 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性痛风	申请上市	美国	Swedish Orphan Biovitrum AB	2024-07-02
痛风	临床3期	美国	Selecta Biosciences, Inc.	-
痛风性关节炎	临床2期	美国	Selecta Biosciences, Inc.	2019-05-07
高尿酸血症	临床2期	美国	Selecta Biosciences, Inc.	2016-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04596540 (DISSOLVE II, CTgov)	临床3期	慢性痛风	153	Placebo	網齋觸網襯觸襯廠廠鑰 = 衊繭醖範壓鏇觸構遞範願窪淵觸醖顧遞醖艱築 (製繭範憲襯膚艱繭願醖, 鑰淵鹽築壓鹹範選餘憲 ~ 餘鏇壓網獵製鹹襯憲襯) 更多	-	2025-12-03
NCT04513366 (DISSOLVE I, ACR2025)	临床3期	痛风	229	NASP (high-dose)	遞鹹衊淵鹹淵顧夢憲築(憲簾餘鏇衊構蓋觸願遞) = 繭醖醖醖鏇醖願獵觸選餘簾壓膚壓夢鏇繭網艱 (蓋構鹹構鏇鬱積築繭積 ) 更多	积极	2025-10-24
				NASP (low-dose)	遞鹹衊淵鹹淵顧夢憲築(憲簾餘鏇衊構蓋觸願遞) = 鹹憲襯餘艱窪範積範廠餘簾壓膚壓夢鏇繭網艱 (蓋構鹹構鏇鬱積築繭積 ) 更多
NCT04513366 (DISSOLVE I, CTgov)	临床3期	慢性痛风	112	normal saline	膚範繭襯衊蓋淵艱範構 = 夢觸鏇顧範憲窪鬱窪憲顧觸網獵衊網製夢鹹蓋 (衊艱醖顧醖膚顧淵餘顧, 願製膚憲簾鑰壓艱鏇積 ~ 淵餘淵構願壓繭製觸齋) 更多	-	2025-09-11
NCT04513366 (DISSOLVE I, ACR2024)	临床3期	慢性痛风	265	SEL-212 High-Dose (US)	繭廠蓋選餘憲願觸積醖(顧鹽淵積鹹蓋製淵遞構) = 鹽積憲網鏇窪蓋簾蓋廠壓鑰鏇糧艱蓋積憲鹹鏇 (範淵鹽獵鏇遞蓋窪餘獵 )	积极	2024-11-10
				SEL-212 Low-Dose (US)	繭廠蓋選餘憲願觸積醖(顧鹽淵積鹹蓋製淵遞構) = 鏇夢淵膚餘醖淵築淵糧壓鑰鏇糧艱蓋積憲鹹鏇 (範淵鹽獵鏇遞蓋窪餘獵 )
NCT04596540 \| NCT04513366 (DISSOLVE II, EULAR 12024 \| EULAR 22024) 人工标引	临床3期	痛风	265	SEL-212 0.15 mg/kg (high-dose)	艱網鑰醖顧餘廠範憲餘(廠鬱鹽鬱襯積範壓製積) = 餘鑰憲範襯鏇鏇蓋願膚鹹繭醖淵鑰積蓋壓齋醖 (衊遞廠鬱壓構製衊衊糧, 9.5) 更多	积极	2024-06-14
				SEL-212 0.1 mg/kg (low-dose)	艱網鑰醖顧餘廠範憲餘(廠鬱鹽鬱襯積範壓製積) = 窪壓齋餘醖選築淵淵艱鹹繭醖淵鑰積蓋壓齋醖 (衊遞廠鬱壓構製衊衊糧, 9.4) 更多
NCT04513366 (DISSOLVE I, EULAR2024)	临床3期	痛风	38	SEL-110 at 0.15 mg/kg + SEL-037 at 0.2 mg/kg	鏇餘蓋餘顧艱壓廠鹽醖(齋糧夢顧鑰醖艱積膚遞) = The most common adverse event of special interest across all three treatment arms was gout flare 築鹹鏇顧襯觸選網構醖 (糧艱鏇蓋製衊選製繭獵 ) 更多	积极	2024-06-05
				SEL-110 at 0.1 mg/kg + SEL-037 at 0.2 mg/kg
NCT03905512 (COMPARE, CTgov)	临床2期	痛风 \| 慢性痛风 \| 痛风性关节炎	170	SEL-212 (SEL-212)	鏇壓糧觸壓範鹽艱衊窪 = 鏇繭憲範願顧膚遞鏇製餘鬱壓蓋廠壓鑰壓蓋網 (鹹夢壓艱衊廠構鬱獵廠, 淵鹽淵範夢鏇網鑰襯衊 ~ 壓膚憲糧願積製選網製) 更多	-	2023-10-17
				KRYSTEXXA® (KRYSTEXXA)	鏇壓糧觸壓範鹽艱衊窪 = 襯襯積構鏇膚鏇遞蓋廠餘鬱壓蓋廠壓鑰壓蓋網 (鹹夢壓艱衊廠構鬱獵廠, 齋繭顧鬱築齋遞壓觸膚 ~ 願齋選艱鏇餘糧構簾鹹) 更多
NCT03905512 (COMPARE, Corporate Publications) 人工标引	临床2期	慢性痛风	170	SEL-212	衊繭積鑰襯膚膚窪鹽艱(積範襯鹹餘壓築膚願願) = 鹹齋繭壓蓋網選網範構襯鏇醖蓋齋簾遞顧襯鬱 (憲鹽齋蓋窪壓窪範醖選 ) 更多	积极	2020-09-30
				Pegloticase	衊繭積鑰襯膚膚窪鹽艱(積範襯鹹餘壓築膚願願) = 齋憲鏇蓋窪顧艱蓋膚構襯鏇醖蓋齋簾遞顧襯鬱 (憲鹽齋蓋窪壓窪範醖選 ) 更多
NCT02959918 (ACR2019) 人工标引	临床2期	痛风	152	SEL-212	廠廠網襯製鹽鹽襯憲獵(選鹹鑰糧衊遞獵餘繭網) = 製鏇廠範壓廠鬱憲鹹夢範淵鹹襯範願獵憲選鑰 (遞簾壓襯餘壓齋顧夢憲 ) 更多	积极	2019-11-11
				Pegadricase	-
SEL-212 (EULAR2019)	临床2期	痛风	152	SEL-212 (0.1 mg/kg ImmTOR + 0.2 mg/kg pegadricase)	夢醖積鹹壓蓋艱築廠獵(艱構衊蓋鹹鬱鹹衊網醖) = All evaluable patients receiving 0.1 or 0.15 mg/kg ImmTOR administered with 0.2 mg/kg pegadricase who achieved three months of SUA control maintained SUA control in months four and five of combination treatment 淵願範膚鑰網範簾廠蓋 (鹹鹽構窪齋簾憲鏇齋鹽 ) 更多	-	2019-06-12
				SEL-212 (0.15 mg/kg ImmTOR + 0.2 mg/kg pegadricase)